Follow us
CANCER DETECTION
By detecting multiple cancers with a single test, we are streamlining the diagnostic process and paving the way for earlier intervention, even in cancers for witch no blood biomarker is available.
hPG80 is Significantly Higher in Cancers Patients
Case-control studies have shown that hPG80 is found at significantly higher levels in the plasma of patients with various types of cancer than in healthy donors.
Bar plots showing hPG80 levels in healthy subjects (n=1,199) and in patients with different types of cancer (n=4,085).
Adapted from You et al. 2020; Kohli et al. 2021, Dupuy et al. 2022; Chauhan et al. 2022; Prieur et al. 2023; Doucet et al. 2023; Hofman et al. ESMO 203, data on file.
Tested Across More than 16 Different Cancer Types
Adapted from You et al. 2020; Kohli et al. 2021, Dupuy et al. 2022; Chauhan et al. 2022; Prieur et al. 2023; Doucet et al. 2023; Hofman et al. ESMO 203, data on file.
Bar plots showing hPG80 levels in healthy subjects (n=1,199) and in patient samples from 16 different types of cancer at various stages:
-
712 breast,
-
608 prostate,
-
829 lung,
-
386 colorectal,
-
319 liver,
-
305 gynecologic,
-
232 kidney,
-
140 esophagus/stomach,
-
133 skin melanoma,
-
129 neuroendocrine,
-
108 pancreas,
-
104 brain,
-
49 head&neck,
-
31 uveal melanoma.
As the global cancer burden continues to rise, with cases projected to exceed 28 million by 2040 (a 47% increase compared to 2020), the importance of early detection becomes critical. Early detection has been shown to greatly enhance cancer survival rates while also increases the chances for successful outcomes.
Detection of hPG80 at Early-Stage Non-Small-Cell Lung Cancer
Bar plots showing hPG80 levels in healthy subjects (n=1,199) and in patient samples (n=2,629) from 16 different types of cancer with stage I (n=390), stage II (n=374), stage III (n=284) and stage IV (n=1,581).
Data on file
In the United States, only 21% of cases are diagnosed at an early stage (localized – confined to primary site) when the five-year survival rate is much higher (62.8%). Unfortunately, 53% of cases are not detected until a late stage (distant – cancer has metastasized), when the survival rate drops to just 8.2%.
Source: SEER 22 (Excluding IL/MA) 2013–201,9 All Races, Both Sexes by SEER Combined Summary Stage
Lung cancer is the deadliest cancer worldwide, accounting for 1.8 million deaths in 2022. When lung cancer is caught early enough to be localized, survival rates can improve dramatically.
Significantly Higher hPG80 Levels in NSCLC Patients, Even at Early Stages
Using a retrospective case-control cohort of 396 patients with non-small-cell-lung cancer (NSCLC) and 330 healthy subjects, we demonstrated that hPG80 levels are significantly higher in NSCLC patients than in healthy subjects.
hPG80 levels were already elevated in stage I NSCLC and maintained at high levels with disease progression, with no statistically significant differences between stages, except between stage I and III (p=0.033).
Dot plots showing hPG80 levels in healthy subjects (n=330), in all NSCLC patients (n=396) and in NSCLC patients’ subgroups based on cancer stages (stage I, n=100; stage II, n=100; stage III, n=97; stage IV, n=99).
Adapted from Hofman et al. ESMO 2023, data on file.
Plasma hPG80 levels in NSCLC patients and healthy subjects. IQR: interquartile range
High Diagnostic Performance of hPG80 in NSCLC
Receiver operating characteristic curves (ROC) of hPG80 in differentiating patients with NSCLC at various stages from healthy subjects or in differentiating stage I to IV NSCLC patients from healthy subjects. AUC: Area under the curve, 95% CI: 95% confidence interval.
All Stages
By Stages
Adapted from Hofman et al. ESMO 2023, data on file.
Hepatocellular carcinoma (HCC) is the 7th most common cancer overall and the 3rd leading cause of cancer-related death worldwide. Early detection is crucial because prognosis is closely linked to the tumor stage at diagnosis. However, many HCC patients are still diagnosed at advanced stages when a cure is no longer possible.
Source: SEER 22 (Excluding IL/MA) 2014–2020, All Races, Both Sexes by SEER Combined Summary Stage
Superior Performance of hPG80 Compared to AFP in Detecting Early-Stage HCC
Serum AFP levels are commonly used for monitoring individuals at risk, but its sensitivity for early HCC detection is low, and it is more frequently elevated in advanced stages of the disease.
Using a retrospective cohort of 168 hepatocellular carcinoma patients, we demonstrated superior performance of hPG80 in detecting early and intermediate stages compared to AFP.
Bar plots showing sensitivities of hPG80 and AFP according to their respective cut-offs values (4.5 pM for hPG80 and 100 ng/mL for AFP) for early, intermediate and advanced hepatocellular carcinoma.
Adapted from Dupuy et al. 2022